Moreover, knockdown of BTRC could increase ATGL levels, inhibit TAG accumulation, and ameliorate hepatic steatosis, suggesting the potential of targeting BTRC for the treatment of NAFLD. The gene discussed is PNPLA2; the disease is Hepatic steatosis.